Showing results (151-160 of 192) with videos related to

Sort By:
Pageof 20
The Journal of Clinical Investigation|June 29, 2018
ATR kinase inhibitor AZD6738 potentiates CD8+ T cell-dependent antitumor activity following radiationFrank P Vendetti, Pooja Karukonda, David A Clump, et al.
Biorxiv : the Preprint Server for Biology|June 17, 2024
Deoxyuridine-rich cytoplasmic DNA antagonizes STING-dependent innate immune responses and sensitizes resistant tumors to anti-PD-L1 therapyPinakin Pandya, Frank P Vendetti, Joseph El-Ghoubaira, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 23, 2012
Phase II study of the multitargeted tyrosine kinase inhibitor XL647 in patients with non-small-cell lung cancerM Catherine Pietanza, Shirish M Gadgeel, Afshin Dowlati, et al.
Cancer Chemotherapy and Pharmacology|August 4, 2017
Phase I study of veliparib in combination with gemcitabineRonald Stoller, John C Schmitz, Fei Ding, et al.
Cancer Research Communications|October 17, 2025
The ATR Inhibitor Elimusertib in Combination with Cisplatin in Patients with Advanced Solid Tumors: A California Cancer Consortium Phase I Trial (NCI 10404)Mamta Parikh, Nataliya V Uboha, Naoko Takebe, et al.
Cell Reports|September 21, 2022
Thymidine rescues ATR kinase inhibitor-induced deoxyuridine contamination in genomic DNA, cell death, and interferon-α/β expressionNorie Sugitani, Frank P Vendetti, Andrew J Cipriano, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 21, 2017
Anti-Platelet-Derived Growth Factor Receptor Alpha Chain Antibodies Predict for Response to Nilotinib in Steroid-Refractory or -Dependent Chronic Graft-Versus-Host DiseaseGeorge L Chen, Paul A Carpenter, Raewyn Broady, et al.
Gynecologic Oncology|January 17, 2017
Chemotherapy completion in elderly women with ovarian, primary peritoneal or fallopian tube cancer - An NRG oncology/Gynecologic Oncology Group studyVivian E von Gruenigen, Helen Q Huang, Jan H Beumer, et al.
Gynecologic Oncology|March 26, 2017
A phase I pharmacokinetic study of intraperitoneal bortezomib and carboplatin in patients with persistent or recurrent ovarian cancer: An NRG Oncology/Gynecologic Oncology Group studyDanielle A Jandial, William E Brady, Stephen B Howell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 24, 2019
Safety and Efficacy of T-DM1 Plus Neratinib in Patients With Metastatic HER2-Positive Breast Cancer: NSABP Foundation Trial FB-10Jame Abraham, Albert J Montero, Rachel C Jankowitz, et al.
Pageof 20